ARTICLE | Clinical News
Flibanserin regulatory update
October 11, 2010 7:00 AM UTC
Boehringer Ingelheim discontinued development of flibanserin to treat hypoactive sexual desire disorder (HSDD) after FDA issued a complete response letter in August. The company said it made the decis...